Literature DB >> 21647651

Cryptogenic chronic hepatitis and its changing guise in adults.

Albert J Czaja1.   

Abstract

Cryptogenic chronic hepatitis is a disease that is unexplained by conventional clinical, laboratory and histological findings, and it can progress to cirrhosis, develop hepatocellular carcinoma, and require liver transplantation. The goals of this review are to describe the changing phenotype of cryptogenic chronic hepatitis in adults, develop a diagnostic algorithm appropriate to current practice, and suggest treatment options. The frequency of cryptogenic hepatitis is estimated at 5.4%. Cryptogenic cirrhosis is diagnosed in 5-30% of patients with cirrhosis, and it is present in 3-14% of adults awaiting liver transplantation. Nonalcoholic fatty liver disease has been implicated in 21-63% of patients, and autoimmune hepatitis is a likely diagnosis in 10-54% of individuals. Viral infections, hereditary liver diseases, celiac disease, and unsuspected alcohol or drug-induced liver injury are recognized infrequently in the current cryptogenic population. Manifestations of the metabolic syndrome heighten the suspicion of nonalcoholic fatty liver disease, and the absence of hepatic steatosis does not discount this possibility. The diagnostic scoring system of the International Autoimmune Hepatitis Group can support the diagnosis of autoimmune hepatitis in some patients. Certain genetic mutations may have disease-specificity, and they suggest that some patients may have an independent and uncharacterized disease. Corticosteroid therapy is effective in patients with autoimmune features, and life-style changes and specific therapies for manifestations of the metabolic syndrome are appropriate for all obese patients. The 1- and 5-year survivals after liver transplantation have ranged from 72-85% to 58-73%, respectively.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21647651     DOI: 10.1007/s10620-011-1769-9

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  206 in total

1.  Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.

Authors:  Yun Ma; Manabu Okamoto; Mark G Thomas; Dimitrios P Bogdanos; Agnel R Lopes; Bernard Portmann; James Underhill; Ralf Dürr; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

2.  [Hereditary hemochromatosis, alpha-1-antitrypsin deficiency and Wilson's disease. Pathogenesis, clinical findings and pathways to diagnosis].

Authors:  H Zhou; H-P Fischer
Journal:  Pathologe       Date:  2008-02       Impact factor: 1.011

3.  Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study.

Authors:  Arie Regev; Constanza Guaqueta; Enrique G Molina; Andrew Conrad; Vishnu Mishra; Mark L Brantly; Maria Torres; Maria De Medina; Andreas G Tzakis; Eugene R Schiff
Journal:  J Pediatr Gastroenterol Nutr       Date:  2006-07       Impact factor: 2.839

4.  C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis.

Authors:  P Lal; H Fernandes; B Koneru; E Albanese; M Hameed
Journal:  Arch Pathol Lab Med       Date:  2000-11       Impact factor: 5.534

5.  Associations between alleles of the major histocompatibility complex and type 1 autoimmune hepatitis.

Authors:  A J Czaja; M D Strettell; L J Thomson; P J Santrach; S B Moore; P T Donaldson; R Williams
Journal:  Hepatology       Date:  1997-02       Impact factor: 17.425

Review 6.  SEN virus: epidemiology and characteristics of a transfusion-transmitted virus.

Authors:  Jun Akiba; Takeji Umemura; Harvey J Alter; Masamichi Kojiro; Edward Tabor
Journal:  Transfusion       Date:  2005-07       Impact factor: 3.157

7.  Cryptogenic liver disease in HIV-seropositive men.

Authors:  M H Dinh; V Stosor; S M Rao; F H Miller; R M Green
Journal:  HIV Med       Date:  2009-05-06       Impact factor: 3.180

8.  Preferential X chromosome loss but random inactivation characterize primary biliary cirrhosis.

Authors:  Monica Miozzo; Carlo Selmi; Barbara Gentilin; Francesca R Grati; Silvia Sirchia; Sabine Oertelt; Massimo Zuin; M Eric Gershwin; Mauro Podda; Pietro Invernizzi
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

9.  Management of hepatocellular carcinoma: an update.

Authors:  Jordi Bruix; Morris Sherman
Journal:  Hepatology       Date:  2011-03       Impact factor: 17.425

Review 10.  Drug-induced autoimmune-like hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-02-16       Impact factor: 3.487

View more
  20 in total

1.  Cryptogenic hepatitis and bartonellosis.

Authors:  Paulo Eduardo Neves Ferreira Velho; Marna Elise Ericson
Journal:  Dig Dis Sci       Date:  2012-02-04       Impact factor: 3.199

Review 2.  Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2017-07-14       Impact factor: 3.199

3.  Searching for unknown transfusion-transmitted hepatitis viruses: a binational cohort study of 1.5 million transfused patients.

Authors:  G Edgren; H Hjalgrim; K Rostgaard; V Dahl; K Titlestad; C Erikstrup; A Wikman; R Norda; A Majeed
Journal:  J Intern Med       Date:  2018-04-25       Impact factor: 8.989

Review 4.  Undiagnosed liver diseases.

Authors:  Emily Gao; Julian Hercun; Theo Heller; Sílvia Vilarinho
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 5.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 6.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

7.  Keratin 8 variants are associated with cryptogenic hepatitis.

Authors:  Mario Zierden; Arndt-Hendrik Penner; Manuel Montesinos-Rongen; Maren Weferling; Uta Drebber; Judith Stift; Jochen W U Fries; Margarete Odenthal; Stephan Rosenkranz; Hans-Peter Dienes
Journal:  Virchows Arch       Date:  2012-03-15       Impact factor: 4.064

8.  The Enigma of Hepatitis E Virus.

Authors:  Liza Bronner Murrison; Kenneth E Sherman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-08

Review 9.  Acute and acute severe (fulminant) autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-10-23       Impact factor: 3.199

Review 10.  Diagnosis, pathogenesis, and treatment of autoimmune hepatitis after liver transplantation.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-05-06       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.